Stefan Sleijfer

28.0k total citations · 2 hit papers
379 papers, 13.6k citations indexed

About

Stefan Sleijfer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Stefan Sleijfer has authored 379 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Oncology, 160 papers in Pulmonary and Respiratory Medicine and 108 papers in Cancer Research. Recurrent topics in Stefan Sleijfer's work include Cancer Genomics and Diagnostics (85 papers), Sarcoma Diagnosis and Treatment (72 papers) and Cancer Cells and Metastasis (43 papers). Stefan Sleijfer is often cited by papers focused on Cancer Genomics and Diagnostics (85 papers), Sarcoma Diagnosis and Treatment (72 papers) and Cancer Cells and Metastasis (43 papers). Stefan Sleijfer collaborates with scholars based in Netherlands, Belgium and United States. Stefan Sleijfer's co-authors include Jaap Verweij, John A. Foekens, John W.M. Martens, Jan W. Gratama, Reno Debets, C. B. H. W. Lamers, Anieta M. Sieuwerts, Agnes Jager, Jaco Kraan and Bianca Mostert and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Stefan Sleijfer

375 papers receiving 13.4k citations

Hit Papers

Treatment of Metastatic R... 2009 2026 2014 2020 2013 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
    2013 561 citations Stefan Sleijfer, Reno Debets et al. profile →
  2. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stefan Sleijfer 7.1k 4.7k 4.2k 3.5k 1.5k 379 13.6k
François Bertucci 8.9k 1.2× 4.8k 1.0× 7.5k 1.8× 5.4k 1.5× 2.7k 1.8× 515 18.8k
Sabino De Placido 7.8k 1.1× 4.5k 1.0× 4.4k 1.0× 3.7k 1.1× 645 0.4× 381 14.0k
William Novotny 12.5k 1.7× 5.7k 1.2× 8.0k 1.9× 3.8k 1.1× 1.5k 1.0× 110 22.6k
Suzette Delaloge 8.4k 1.2× 3.8k 0.8× 3.4k 0.8× 5.0k 1.4× 1.2k 0.8× 399 13.9k
Luc Dirix 9.4k 1.3× 3.4k 0.7× 4.4k 1.1× 4.6k 1.3× 1.4k 0.9× 311 14.6k
Joseph A. Sparano 10.4k 1.5× 2.7k 0.6× 3.7k 0.9× 5.3k 1.5× 1.7k 1.2× 397 15.9k
Andreas Schneeweiß 13.3k 1.9× 4.4k 0.9× 4.6k 1.1× 8.3k 2.4× 1.7k 1.2× 608 19.1k
Ahmad Awada 9.5k 1.3× 4.8k 1.0× 5.2k 1.2× 3.0k 0.8× 1.1k 0.8× 542 16.2k
John Crown 13.0k 1.8× 4.8k 1.0× 7.4k 1.8× 6.0k 1.7× 1.7k 1.1× 416 20.1k
Gabriella Sozzi 5.2k 0.7× 5.0k 1.1× 7.6k 1.8× 4.5k 1.3× 760 0.5× 283 15.0k

Countries citing papers authored by Stefan Sleijfer

Since Specialization
Citations

This map shows the geographic impact of Stefan Sleijfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Sleijfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Sleijfer more than expected).

Fields of papers citing papers by Stefan Sleijfer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Sleijfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Sleijfer. The network helps show where Stefan Sleijfer may publish in the future.

Co-authorship network of co-authors of Stefan Sleijfer

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Sleijfer. A scholar is included among the top collaborators of Stefan Sleijfer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Sleijfer. Stefan Sleijfer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jansen, Maurice P.H.M., Jaco Kraan, Corine M. Beaufort, et al.. (2024). Circulating tumor cells and tumor DNA in patients with resectable colorectal liver metastases: The MIRACLE.. Journal of Clinical Oncology. 42(16_suppl). 3011–3011. 1 indexed citations
2.
Kraan, Jaco, Martijn P. A. Starmans, Jean Helmijr, et al.. (2024). Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma. Molecular Oncology. 18(11). 2770–2782. 1 indexed citations
3.
Weerd, Vanja de, Mai N. Van, Jaco Kraan, et al.. (2023). Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival. npj Breast Cancer. 9(1). 61–61. 6 indexed citations
4.
Oosting, Sjoukje F., C. Willemien Menke‐van der Houven van Oordt, Ruben Boers, et al.. (2023). Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting. Cancers. 15(5). 1374–1374. 5 indexed citations
5.
Angus, Lindsay, Marcel Smid, Saskia M. Wilting, et al.. (2023). Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling. Cancers. 15(17). 4416–4416. 3 indexed citations
6.
Wijers, Rebecca, Senada Koljenović, Stefan Sleijfer, et al.. (2022). Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients. Cancers. 14(17). 4298–4298. 6 indexed citations
7.
Schöffski, Patrick, Ahmad Awada, Mike F. Burbridge, et al.. (2022). First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. European Journal of Cancer. 169. 135–145. 21 indexed citations
8.
Groenendijk, Floris H., Debbie Robbrecht, Winand N.M. Dinjens, et al.. (2022). Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer. 127(4). 776–783. 3 indexed citations
9.
Jongbloed, Elisabeth M., et al.. (2021). A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients. Cancers. 13(8). 1811–1811. 6 indexed citations
10.
Smid, Marcel, Job van Riet, Lindsay Angus, et al.. (2021). Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications. 12(1). 3269–3269. 6 indexed citations
11.
Mir, Olivier, Nathan Touati, Michela Lia, et al.. (2019). Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clinical Cancer Research. 25(5). 1479–1485. 64 indexed citations
12.
Basak, Edwin A., Stijn L.W. Koolen, Daan P. Hurkmans, et al.. (2019). Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer. European Journal of Cancer. 109. 12–20. 54 indexed citations
13.
IJzendoorn, David G.P. van, Stefan Sleijfer, Hans Gelderblom, et al.. (2018). Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clinical Cancer Research. 24(11). 2678–2687. 35 indexed citations
14.
Weerts, Marjolein J.A., Antoinette Hollestelle, Anieta M. Sieuwerts, et al.. (2017). Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. Clinical Cancer Research. 23(16). 4735–4743. 16 indexed citations
15.
Rier, Hánah N., Agnes Jager, Stefan Sleijfer, et al.. (2016). Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. The Breast. 31. 9–15. 123 indexed citations
16.
Onstenk, Wendy, Jaco Kraan, Bianca Mostert, et al.. (2014). Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics. 14(3). 821–827. 47 indexed citations
17.
Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →
18.
Mom, Constantijne H., Jaap Verweij, Corina N.A.M. Oldenhuis, et al.. (2009). Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clinical Cancer Research. 15(17). 5584–5590. 85 indexed citations
19.
Helleman, Jozien, Maurice P.H.M. Jansen, Kirsten Ruigrok-Ritstier, et al.. (2008). Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. Clinical Cancer Research. 14(17). 5555–5564. 142 indexed citations
20.
Sleijfer, Stefan, et al.. (2005). A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies.. Data Archiving and Networked Services (DANS). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by François Bertucci Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by William Novotny Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Luc Dirix Breakdown of academic impact, for papers by Joseph A. Sparano Breakdown of academic impact, for papers by Andreas Schneeweiß Breakdown of academic impact, for papers by Ahmad Awada Breakdown of academic impact, for papers by John Crown Breakdown of academic impact, for papers by Gabriella Sozzi
Rankless by CCL
2026